Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

DEXLANSOPRAZOLE DR 30 MG CAP

Dexlansoprazole
$4.4485per EA

Strength

30 mg/1

Manufacturer

Endo USA Inc.

NDC

49884014711

Classification

Generic

Dosage Form

CAPSULE, DELAYED RELEASE

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

DEXLANSOPRAZOLE

Approval Type

Generic (ANDA)

FDA Application

ANDA202294

On Market Since

6/10/2023

Pharmacological Classes

Proton Pump Inhibitor
Proton Pump Inhibitors

Price History

1W

0.0%

1M

-4.6%

3M

-8.0%

6M

+2.2%

1Y

+0.3%

3Y

N/A

5Y

N/A

All

-39.8%

Generic Alternatives

1 alternative • Same active ingredient

DEXLANSOPRAZOLE DR 30 MG CAP
Generic
62332082330•Alembic Pharmaceuticals Inc.
$4.4485

Related Drugs

Same classification

OMEPRAZOLE DR 20 MG CAPSULE
Generic
00781286801•Sandoz Inc.
$0.0285
per EA
OMEPRAZOLE DR 20 MG CAPSULE
Generic
00781286810•Sandoz Inc.
$0.0285
per EA
OMEPRAZOLE DR 20 MG CAPSULE
Generic
00781286831•Sandoz Inc.
$0.0285
per EA
OMEPRAZOLE DR 20 MG CAPSULE
Generic
00781286892•Sandoz Inc.
$0.0285
per EA
OMEPRAZOLE DR 20 MG CAPSULE
Generic
00904691761•Major Pharmaceuticals
$0.0285
per EA
OMEPRAZOLE DR 20 MG CAPSULE
Generic
16714063401•NorthStar Rx LLC
$0.0285
per EA
OMEPRAZOLE DR 20 MG CAPSULE
Generic
16714063402•NorthStar Rx LLC
$0.0285
per EA
OMEPRAZOLE DR 20 MG CAPSULE
Generic
16714063403•NorthStar Rx LLC
$0.0285
per EA
OMEPRAZOLE DR 20 MG CAPSULE
Generic
16714071501•NorthStar Rx LLC
$0.0285
per EA
OMEPRAZOLE DR 20 MG CAPSULE
Generic
16714071502•NorthStar Rx LLC
$0.0285
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy